Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABCL vs ABSI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABCL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

ABCL Overall Winner 6-Pillar Tally: ABCL 5 – 0 ABSI (1 Tie) Matrix Metrics: ABCL 8 – 2 ABSI

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Absci Corporation (ABSI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABCL carries a Unified Composite Score of 63.3/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin), whereas ABSI carries 41.2/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin).

  • Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (63.3/100 BUY vs. ABSI 41.2/100 SELL) and 2.31β · 87% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.3); meanwhile ABSI is in a Breakdown options structure phase (RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABCL vs ABSI
ABCL NASDAQ Head-to-Head Winner
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap $3.8B
TTM Revenue $66M
Forward P/E 27.6x
Beta / 30D Vol 2.31β · 87% Vol
Unified Composite Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.3 · SMA20: $12.04 · SMA50: $12.33
ABSI NASDAQ
Absci Corporation Common Stock
Services-Commercial Physical & Biological Research
$7.72
-8.58% 1D
Market Cap $1.6B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 3.31β · 126% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 30.0 Fund 51.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $9.94 · SMA50: $9.63

6-Pillar Scorecard Institutional Category Breakdown (ABCL 5 – 0 ABSI)

Columns: Metric · ABCL · ABSI
1. Valuation Multiples ABCL
Forward P/E 27.6x N/M
Trailing P/E 27.6x N/M
PEG Ratio N/M N/M
EV / Revenue 56.9x N/M
2. Growth & Scale ABCL
Revenue Growth (YoY) -76.3% -19.6%
Earnings Growth (YoY) +45.9% +0.0%
TTM Revenue (USD) $66M $1.5M
Market Cap $3.8B $1.6B
3. Profitability & Quality ABCL
Gross Margin N/A N/A
Operating Margin -1550.0% -9108.3%
Net Profit Margin -248.8% 0.0%
Return on Equity (ROE) -17.3% -58.6%
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) -$33M -$112M
Cash Flow Margin -49.6% N/A
Net Cash / Leverage $30M Net Cash $10M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABCL
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 80.8% (25th %ile) 169.1% (15th %ile)
Put/Call OI Skew 0.23x (Call-Skewed) 0.57x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABCL (8) vs ABSI (2)
Institutional Metric ABCL ABSI Criterion Row Edge
Market Capitalization
Scale
$3.8B $1.6B Larger Scale ABCL
Trailing P/E Ratio
Valuation
27.6x N/M Lower Multiple ABCL
Forward P/E Ratio
Valuation
27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY)
Growth
-76.3% -19.6% Higher Growth ABSI
Operating Margin (TTM)
Profitability
-1550.0% -9108.3% Higher Margin ABCL
Net Profit Margin
Profitability
-248.8% 0.0% Higher Margin ABSI
Return on Equity (ROE)
Capital Efficiency
-17.3% -58.6% Higher ROE ABCL
52-Week Range Position
Momentum
69% ($3–$15) 53% ($2–$13) Stronger Trend ABCL
Beta / 30D Volatility
Risk Regime
2.31β · 87% Vol 3.31β · 126% Vol Lower Realized Risk ABCL
Unified Institutional Score
Composite Signal
63.3 / 100 (BUY) 41.2 / 100 (SELL) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
$66M $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 56.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$33M ($30M Net Cash) -$112M ($10M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABCL +1.15 pp
ABCL: -5.21% · ABSI: -6.36%
3M Horizon ABCL +13.29 pp
ABCL: +0.58% · ABSI: -12.71%
6M Horizon ABCL +112.65 pp
ABCL: +168.87% · ABSI: +56.22%
1Y Horizon ABCL +16.37 pp
ABCL: +208.98% · ABSI: +192.61%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ABCL Revenue ABSI Revenue ABCL Op. Margin ABSI Op. Margin Margin Leader
FY2019 $10M N/A -35.5% N/A ABCL
FY2020 $230M $0M 66.9% -278.3% ABCL
FY2021 $380M $0M 54.5% -1573.4% ABCL
FY2022 $490M $10M 44.6% -1857.5% ABCL
FY2023 $40M $10M -623.8% -2020.2% ABCL
FY2024 $30M $0M -1091.7% -2401.6% ABCL
FY2025 $80M $0M -289.0% -4297.0% ABCL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABCL CONSOLIDATION
34d in phase · OBV NEUTRAL
Current IV 80.8%
IV Percentile 25th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABSI BREAKDOWN
97d in phase · OBV NEUTRAL
Current IV 169.1%
IV Percentile 15th %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABSI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and -9108.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABCL vs ABSI Key Questions & Quantitative Answers

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Absci Corporation (ABSI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABCL carries a Unified Composite Score of 63.3/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin), whereas ABSI carries 41.2/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin). Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (63.3/100 BUY vs. ABSI 41.2/100 SELL) and 2.31β · 87% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.3); meanwhile ABSI is in a Breakdown options structure phase (RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABCL leads the Growth & Scale pillar: ABCL posts -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin), compared with ABSI at -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ABCL cumulative revenue shifted +700.0% while ABSI shifted +0.0%. In operating R&D and SG&A reinvestment, ABCL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABSI.

ABCL screens cheaper on headline valuation multiples. ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin), whereas ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABCL (-17.3% ROE) versus ABSI (-58.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ABCL carries 80.8% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.31β · 87% Vol realized risk). By comparison, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.31β · 126% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.